Extended interval dosing of natalizumab: a two-center, 7-year experience
Open Access
- 24 June 2014
- journal article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 7 (5), 227-231
- https://doi.org/10.1177/1756285614540224
Abstract
Background: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple sclerosis (MS), has been tempered by the risks of progressive multifocal leukoencephalopathy associated with its use, and strategies to minimize those risks are of great interest. Extended interval dosing (EID) has been proposed as a way to maintain the efficacy of natalizumab while reducing exposure to it. We reviewed a cohort of patients who received natalizumab at 6–8-week intervals instead of the typical infusions every 4 weeks with the goal to assess if patients on EID had an increase in clinical relapses. Methods: This is a retrospective review of all patients with MS treated with natalizumab at two MS centers where patients were offered the opportunity to switch to an EID every 6 or 8 weeks. Results: A total of 361 patients received natalizumab for 22 ± 13 months (minimum duration 6 months). Of these, 96 patients received EID natalizumab at some point for 20 ± 11 months (minimum duration 6 months). Over the study period, there was no significant difference between the relapse rate in the monthly dosing (13%) and the EID (13%) groups of patients. Conclusion: Natalizumab is effective in controlling MS as very few clinical relapses were observed in our dataset. We found that EID did not compromise the treatment effect as measured by relapse rate and no significant breakthrough disease activity was observed. EID is an optional regimen for maintenance natalizumab therapy, but prospective studies are warranted to determine its efficacy.Keywords
This publication has 28 references indexed in Scilit:
- Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational studyZeitschrift für Neurologie, 2012
- From injection therapies to natalizumab: views on the treatment of multiple sclerosisTherapeutic Advances in Neurological Disorders, 2011
- Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringThe Lancet Neurology, 2011
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology, 2011
- Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line TherapyPLOS ONE, 2011
- Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in RomeNeurological Sciences, 2010
- Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in SwitzerlandEuropean Neurology, 2010
- Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi‐center study in German speaking countriesEuropean Journal of Neurology, 2009
- Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapyMultiple Sclerosis Journal, 2009
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyThe Lancet Neurology, 2009